Search

Your search keyword '"Sabik JF 3rd"' showing total 181 results

Search Constraints

Start Over You searched for: Author "Sabik JF 3rd" Remove constraint Author: "Sabik JF 3rd" Database MEDLINE Remove constraint Database: MEDLINE
181 results on '"Sabik JF 3rd"'

Search Results

1. Major Bleeding and Mortality After Revascularization of Left Main Disease.

2. Core Laboratory Versus Center-Reported Echocardiographic Assessment of the Native and Bioprosthetic Aortic Valve.

3. 7-Year outcomes after surgical aortic valve replacement with a stented bovine pericardial bioprosthesis in over 1100 patients: a prospective multicenter analysis.

4. Harmonizing Guidelines and Other Clinical Practice Documents: A Joint Comprehensive Methodology Manual by the American Association for Thoracic Surgery (AATS), European Association for Cardio-Thoracic Surgery (EACTS), European Society of Thoracic Surgeons (ESTS), and Society of Thoracic Surgeons (STS).

5. Harmonizing guidelines and other clinical practice documents: A joint comprehensive methodology manual by the American Association for Thoracic Surgery (AATS), European Association for Cardio-Thoracic Surgery (EACTS), European Society of Thoracic Surgeons (ESTS), and Society of Thoracic Surgeons (STS).

6. Harmonizing guidelines and other clinical practice documents: A joint comprehensive methodology manual by the American Association for Thoracic Surgery (AATS), European Association for Cardio-Thoracic Surgery (EACTS), European Society of Thoracic Surgeons (ESTS), and Society of Thoracic Surgeons (STS).

7. Examining the typical hemodynamic performance of nearly 3000 modern surgical aortic bioprostheses.

8. Multiarterial vs Single-Arterial Coronary Surgery: 10-Year Follow-up of 1 Million Patients.

9. Incidence, Predictors, and Impact of Hospital Readmission After Revascularization for Left Main Coronary Disease.

10. Impact of Incomplete Revascularization After PCI in Left Main Disease: The EXCEL Trial.

11. Do postoperative hemodynamic parameters add prognostic value for mortality after surgical aortic valve replacement?

12. STS/AATS-Endorsed Rebuttal to 2023 ACC/AHA Chronic Coronary Disease Guideline: A Missed Opportunity to Present Accurate and Comprehensive Revascularization Recommendations.

13. STS/AATS-endorsed rebuttal to 2023 ACC/AHA Chronic Coronary Disease Guideline: A missed opportunity to present accurate and comprehensive revascularization recommendations.

14. Outcomes of Surgical Bioprosthetic Aortic Valve Replacement in Patients Aged ≤65 and >65 Years.

15. Minimally Invasive Aortic Valve Replacement in Contemporary Practice: Clinical and Hemodynamic Performance from a Prospective Multicenter Trial.

16. Perioperative care differences of surgical aortic valve replacement between North America and Europe.

18. Endoscopic vs Open Vein Harvest in Drug-Eluting Stents or Bypass Surgery for Left Main Disease Trial.

19. Pledgeted versus nonpledgeted sutures in aortic valve replacement: Insights from a prospective multicenter trial.

20. Association of Volume and Outcomes in 234 556 Patients Undergoing Surgical Aortic Valve Replacement.

21. Why the categorization of indexed effective orifice area is not justified for the classification of prosthesis-patient mismatch.

25. White blood cell count and clinical outcomes after left main coronary artery revascularization: insights from the EXCEL trial.

26. Impact of renin-angiotensin system inhibitors after revascularization of patients with left main coronary artery disease.

27. Outcomes of Vascular Closure Device Use After Transfemoral Coronary Intervention: Insights From the EXCEL Trial.

28. Impact of lesion preparation strategies on outcomes of left main PCI: The EXCEL trial.

29. Implications of Biomarker Discordance After Coronary Artery Revascularization: The EXCEL Trial.

30. Antithrombotic regimens for percutaneous coronary intervention of the left main coronary artery: The EXCEL trial.

32. Outpatient Versus Inpatient Percutaneous Coronary Intervention in Patients With Left Main Disease (from the EXCEL Trial).

33. Antithrombotic therapy and bleeding events after aortic valve replacement with a novel bioprosthesis.

34. Procedural characteristics and clinical outcomes in patients undergoing percutaneous coronary intervention for left main trifurcation disease: the EXCEL trial.

35. Sizing Strategy and Implant Considerations for the Avalus Valve.

36. Effect of red blood cell storage duration on major postoperative complications in cardiac surgery: A randomized trial.

37. Aortic Valve Replacement in Bioprosthetic Failure: Insights From The Society of Thoracic Surgeons National Database.

38. Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization.

39. Coronary Artery Bypass Grafting in Cancer Patients: Prevalence and Outcomes in the United States.

40. Outcomes After Left Main Coronary Artery Revascularization by Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting According to Smoking Status.

41. Influence of final kissing balloon inflation on long-term outcomes after PCI of distal left main bifurcation lesions in the EXCEL trial.

42. Prognostic performance of the Society of Thoracic Surgeons risk score in patients with left main coronary artery disease undergoing revascularisation: a post hoc analysis of the EXCEL trial.

43. Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization: results from the randomized EXCEL trial.

45. Effect of Baseline Anemia on Outcomes After Left Main Coronary Revascularization.

46. Incidence and Prognostic Impact of Atrial Fibrillation After Discharge Following Revascularization for Significant Left Main Coronary Artery Narrowing.

47. Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease: The EXCEL Trial.

48. Usefulness of Discharge Resting Heart Rate to Predict Adverse Cardiovascular Outcomes in Patients With Left Main Coronary Artery Disease Revascularized With Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting (from the EXCEL Trial).

49. Risk Calculator to Predict 30-Day Readmission After Coronary Artery Bypass: A Strategic Decision Support Tool.

50. Stability After Initial Decline in Coronary Revascularization Rates in the United States.

Catalog

Books, media, physical & digital resources